SARS‐CoV2 pneumonia recovery is linked to expansion of innate lymphoid cells type 2 expressing CCR10
| Autor: | Gomes, André, Farias, Guilherme B., Dias Silva, Manuel, Laia, Joel, Trombetta, Amelia Chiara, Godinho-Santos, Ana, Rosmaninho, Pedro, Santos, Diana F., Conceição, Carolina M., Costa Reis, Renato, Adao-Serrano, Maria, Mota, Catarina, Almeida, Afonso, Sousa, Ana E., Fernandes, Susana M. |
|---|---|
| Přispěvatelé: | Repositório da Universidade de Lisboa |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: | |
| Popis: | © 2021 The Authors. European Journal of Immunology published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made. Accelerate lung repair in SARS-CoV-2 pneumonia is essential for pandemic handling. Innate lymphoid cells (ILCs) are likely players, given their role in mucosal protection and tissue homeostasis. We studied ILC subpopulations at two time points in a cohort of patients admitted in the hospital due to SARS-CoV-2 infection. COVID-19 patients with moderate/severe respiratory failure featured profound depletion of circulating ILCs at hospital admission, in agreement with overall lymphocyte depletion. However, ILCs recovered in direct correlation with lung function improvement as measured by oxygenation index and in negative association with inflammatory and lung/endothelial damage markers like RAGE. While both ILC1 and ILC2 expanded, ILC2 showed the most striking phenotype changes, with CCR10 upregulation in strong correlation with these parameters. Overall, CCR10+ ILC2 emerge as relevant contributors to SARS-CoV-2 pneumonia recovery. This work was funded by the following grants from Fundação para a Ciência e a Tecnologia (FCT), Portugal, through “APOIO ESPECIAL RESEARCH4COVID-19,” project numbers 125 to SMF and 803 to ACT. AMCG and GBF received fellowships funded by FCT (DOCTORATES4COVID-19, 2020.10202.BD) and JANSSEN- CILAG FARMACÊUTICA, respectively. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|